MHB088C

MHB088C is an investigational antibody-drug conjugate (ADC) developed by Minghui Pharmaceutical. It consists of a humanized monoclonal antibody targeting the immunoregulatory protein B7-homologue 3 (B7-H3, also known as CD276), conjugated via a cleavable linker to a proprietary DNA topoisomerase I inhibitor payload that is 5–10 times more potent than DXd. The drug is designed for antineoplastic activity and has demonstrated robust binding affinity, superior internalization rates, and potent tumor cell killing in preclinical models—outperforming competitor compounds. Clinical studies have shown promising efficacy and a favorable safety profile without unique toxicities or interstitial lung disease. MHB088C is being evaluated primarily for recurrent or metastatic solid tumors, with registrational trials planned for select cancer types[1][2][3][4][5][6].

Other names

anti-B7-H3 antibody-drug conjugate MHB088Canti-B-7-H3 antibody-drug conjugate MHB088Canti-B 7-H3 antibody-drug conjugate MHB088CB7-H3 ADCB-7-H3 ADCB 7-H3 ADC